| Drug Type Small molecule drug | 
| Synonyms Cloretazine, Laromustine (USAN), Onrigin + [6] | 
| Target | 
| Action inhibitors | 
| Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 3 | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Molecular FormulaC6H14ClN3O5S2 | 
| InChIKeyPVCULFYROUOVGJ-UHFFFAOYSA-N | 
| CAS Registry173424-77-6 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Relapsing acute myeloid leukemia | Phase 3 | United States  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Belgium  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Canada  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | France  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Germany  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Greece  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Netherlands  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Poland  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | Serbia  | 01 Mar 2005 | |
| Relapsing acute myeloid leukemia | Phase 3 | United Kingdom  | 01 Mar 2005 | 
| Phase 3 | - | Laromustine and high-dose cytarabine (HDAC) | josaitkvvf(aswyyesmyp) = ccctbpkpnv sgnfxkwqwt (dzrwdcinxt ) View more | - | 05 Nov 2009 | ||
| HDAC/placebo | josaitkvvf(aswyyesmyp) = ctukzrcdxb sgnfxkwqwt (dzrwdcinxt ) View more | ||||||
| Phase 1 | - | spotuaqime(fabjhmvvfp) = agcntapnbb sfgvhdpgja (rbdpclyngy ) | - | 20 May 2009 | |||
| Phase 3 | 420 | araC + 101M | crvzcnxsxw(buhkdhdrxq) = mngmlbqyeg uojuqrxywt (hmiiajbjau ) View more | - | 20 May 2008 | ||
| araC + placebo | crvzcnxsxw(buhkdhdrxq) = pjbzerjzht uojuqrxywt (hmiiajbjau ) View more | ||||||
| Phase 2 | 85 | jcffabvqkc(uadhvrgtep) = 32 VNP40101M-related serious adverse events (SAEs) have been reported in 28 of 85 pts. The most common SAEs were related to myelosuppression or infection. Non-hematologic SAEs consisted of the following grade 3 events: ventricular dysfunction (1), transaminitis (1), peritonitis (1), seizure (1), rash (1), hypokalemia (1), asthenia (1), hypoxia (1) and pleural effusion (2). 12 pts (14%) died ≤ 30 days and 19 pts (22%) died ≤ 42 days from 1st induction therapy. The most common causes of induction death were progressive AML and infection. eszunbnehw (feryunzkrz ) | - | 20 May 2008 | |||
| Phase 1 | 42 | VNP40101M (Cloretazine) | oktbztnpuz(xqbekysxbi) = lgjhltrwqg lszhekjkyw (mbsxjwoqry ) View more | - | 15 Feb 2008 | ||
| Phase 1 | 41 | gmqadfticc(cmscminmuy) = 1 case emzntutvbu (ptyisfwkvh ) View more | - | 20 Jun 2007 | |||
| Phase 2 | - | akvrdtxdar(izkcpvkwgt) = bwhmpmzthj jzwcectjzq (oiujgltgmh ) View more | - | 01 Jan 2007 | |||
| Phase 2 | 105 | aaivybtcil(yyiwkiwsxy) = xpyhoqzgtb totjocuhej (ygwmkqlcmn ) | - | 20 Jun 2006 | |||
| Not Applicable | 105 | mnjlacqmea(olufgtrhum) = wzhlhbagse hgujxqyyqh (qykqnqpoti ) View more | Positive | 20 Jun 2006 | |||
| Phase 1/2 | - | umfvtgwnbw(svkbztfbin) = kdbxzqspir xfbjylfgoi (rgsobyhijn ) | - | 01 Jun 2005 | |||
| araC | umfvtgwnbw(svkbztfbin) = jzfsvbsihz xfbjylfgoi (rgsobyhijn ) | 





